Zacks Research Issues Pessimistic Outlook for PAHC Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Equities research analysts at Zacks Research dropped their Q4 2027 earnings estimates for Phibro Animal Health in a research report issued on Thursday, June 11th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.78 for the quarter, down from their previous estimate of $0.80. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $3.08 per share.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup dropped their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings cut shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $38.80.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $31.53 on Monday. Phibro Animal Health has a 12-month low of $23.57 and a 12-month high of $60.08. The stock has a market cap of $1.28 billion, a P/E ratio of 13.53, a PEG ratio of 0.48 and a beta of 0.47. The company has a 50-day moving average price of $43.88 and a 200 day moving average price of $44.78. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The firm had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. 1620 Investment Advisors Inc. boosted its stake in shares of Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC lifted its stake in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares during the last quarter. KBC Group NV purchased a new position in Phibro Animal Health in the first quarter worth approximately $29,000. Rothschild Investment LLC lifted its stake in Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Hughes Financial Services LLC purchased a new position in Phibro Animal Health in the third quarter worth approximately $40,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 10,560 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total value of $556,300.80. Following the completion of the transaction, the chief executive officer owned 80,360 shares of the company’s stock, valued at approximately $4,233,364.80. This trade represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 69,648 shares of company stock valued at $3,759,028 over the last ninety days. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised its earnings estimates for Phibro Animal Health across several periods, including FY2026 to $3.05 EPS, FY2027 to $3.18 EPS, and FY2028 to $3.35 EPS, signaling a more constructive view of the company’s earnings power.
• Positive Sentiment: Near-term estimates were also nudged higher, including Q4 2026 to $0.69 EPS, Q1 2027 to $0.79 EPS, Q2 2027 to $0.85 EPS, Q3 2027 to $0.76 EPS, and Q1 2028/Q3 2028 to $0.82 EPS each, which may support investor confidence in execution.
• Neutral Sentiment: Zacks Research kept a Hold rating on PAHC, so the revisions are supportive but not a strong bullish upgrade.
• Neutral Sentiment: The stock still trades well below its 50-day and 200-day moving averages, so the shares remain in a weaker technical position despite the analyst optimism.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.